Analysis Novo Nordisk’s Pipeline Setbacks Test the Patience of Investors Ahead of Earnings
The Danish pharmaceutical giant heads into its quarterly report with a bruised share price and a pipeline narrative that has lost some of its shine. Two clinical disappointments in quick...